Sold as Calcibind. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Cellulose Sodium Phosphate (sold as Calcibind), first approved Dec 28, 1982, with 0 new uses approved and 0 published complete response letters.
| Oral B-Complex Vitamin (B6, B9 and B12) Prevents Low Anterior Resection Syndrome in Rectal Cancer Patients With HyperhomocysteinemiaLow Anterior Resection Syndrome, Hyperhomocysteinemia · Qilu Hospital of Shandong University | Not applicable | Not yet recruiting | Nov 10, 2026 |
| Osteoarthritis Care Tools for Primary Care Providers in Family Medicine and Geriatrics ClinicsArthritis, Osteo Arthritis Knee and Hip · University of North Carolina, Chapel Hill | Not applicable | Not yet recruiting | Nov 9, 2026 |
| Effects of Daily Magnesium Complex Supplementation on Body Composition in University StudentsBody Composition Changes, Muscle Mass · Noakhali Science and Technology University | Not applicable | Not yet recruiting | Oct 30, 2026 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult ParticipantsChronic Pancreatitis · Cibus Therapeutics, Inc. | Phase 1 | Recruiting | Oct 29, 2026 |
| Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's DiseaseHuntington Disease, Sarcopenia · Universidad de Burgos | Not applicable | Not yet recruiting | Oct 28, 2026 |
| Study Comparing Osteoarthritis ProgramsOsteoarthritis · Weill Medical College of Cornell University | Not applicable | Not yet recruiting | Oct 27, 2026 |
| A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite ControlOverweight, Obesity · MNnutra | Not applicable | Active, not recruiting | Oct 26, 2026 |
| Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in AdultsSleep Quality, Magnesium Deficiency · José Enrique de la Rubia Ortí, Ph | Not applicable | Active, not recruiting | Oct 26, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 28, 1982 | CalcibindNDA 18757 · New molecular entity | Mission Pharma | 9 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA